Last reviewed · How we verify
Intravenous Esomeprazole
Intravenous esomeprazole inhibits gastric acid secretion by blocking the proton pump in parietal cells of the stomach.
Intravenous esomeprazole inhibits gastric acid secretion by blocking the proton pump in parietal cells of the stomach. Used for Acute gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis in critically ill patients.
At a glance
| Generic name | Intravenous Esomeprazole |
|---|---|
| Also known as | IV, nexium |
| Sponsor | Chinese University of Hong Kong |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole, a proton pump inhibitor (PPI). It irreversibly binds to and inhibits the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells, thereby suppressing both basal and stimulated gastric acid production. The intravenous formulation provides rapid onset of action for acute acid-related conditions.
Approved indications
- Acute gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Stress ulcer prophylaxis in critically ill patients
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (with long-term use)
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU
- Acid-suppression Drugs After Prophylactic Endoscopic Variceal Treatment of Esophagogastric Variceal Bleeding in Cirrhosis (NA)
- A Phase I Study of LX22001 for Injection in Healthy Subjects (PHASE1)
- Esomeprazole to Reduce Organ Failure in Sepsis (PHASE3)
- Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding (PHASE4)
- The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Esomeprazole CI brief — competitive landscape report
- Intravenous Esomeprazole updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI